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Introduction
Endometrial cancer is the most common malignancy of the 
female reproductive tract in industrialized countries [1]. Sur-
gery is the first major step in the management of this disease, 
and the outcomes of surgery can guide the choice of postop-
erative adjuvant treatment. At present, open surgery (OS), 
laparoscopic surgery (LS), and robotic surgery (RS) can be 
used to treat endometrial cancer [2]. 
Compared to the OS, the LS provides equivalent oncologic 
outcomes with reduced surgical and postoperative morbidity 
[3,4]. However, the steep learning curve associated with the 
LS restricts its widespread application as a surgical treatment 
for endometrial cancer. The introduction of robot-assisted LS 
with a relatively shallower learning curve has encouraged 
more gynecologic oncologists to employ minimally invasive 
surgery (MIS) over the OS when treating endometrial cancer, 
and this has resulted in approximately 80% of patients under-
going hysterectomy for cancer by the RS in the United States 
[5].
Previous research comparing the OS with the LS [6] and the 
LS with the RS exists [7], along with one meta-analysis com-
paring all three approaches [8]. However, data are scarce con-
cerning the direct comparison of survival outcomes among 
the OS, the LS, and the RS for endometrial cancer [9]. Thus, 
the advantage of the RS relative to the LS and the OS in the 
treatment of endometrial cancer has not yet been fully deter-
mined. 
Therefore, in this study, we performed a nationwide pop-
ulation-based cohort study to compare the perioperative and 
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Purpose  Population-based comparisons between minimally invasive surgery (MIS) (robotic surgery [RS] and laparoscopic surgery 
[LS]) and open surgery (OS) for managing endometrial cancer are lacking. This study aimed to compare surgical and oncologic out-
comes between endometrial cancer patients who underwent surgical staging via MIS or OS. 
Materials and Methods  A population-based retrospective cohort study was performed using claims data from the Korean National 
Health Insurance database from January 2012 to December 2016. All patients who underwent hysterectomy under diagnosis of 
endometrial cancer were identified. Patients were classified into RS, LS, and OS groups. Operative and oncologic outcomes were 
compared among the three groups after adjustments for age group, risk group (adjuvant therapy status), modified Charlson comor-
bidity index, income level, insurance type, and index year using propensity scores obtained via the inverse probability of treatment 
weighted method. 
Results  After adjustment, 5,065 patients (RS, n=315; LS, n=3,248; OS, n=1,503) were analyzed. Patient demographics were com-
parable. Hospital stay, postoperative complications, and cost were more favorable in the RS and LS groups than in the OS group (all 
p < 0.001). Five-year overall survival was significantly longer in the RS and LS groups than in the OS group (94.8%, 91.9%, and 86.9%, 
respectively; p < 0.001). Moreover, the survival benefit of RS was shown in the subgroup analysis of low-risk endometrial cancer 
patients.
Conclusion  Our study provides further evidence for the RS being a safe surgical alternative to the LS and OS, especially in low-risk 
endometrial cancer patients, offering surgical and oncologic outcomes equivalent to other surgical approaches.
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1. Study design and database  
We performed a nationwide population-based retrospec-
tive cohort study by investigating the Korean National 
Health Insurance Service (NHIS) claims database from Janu-
ary 2012 to December 2016. The Korean NHIS is a manda-
tory national health insurance program established by the 
government that covers all forms of health-care utilization, 
including pharmaceutical services, outpatient and inpatient 
care, and diagnostic and surgical procedures for the entire 
population (approximately 51 million people). Hospitals 
are required to submit all information regarding health-care 
utilization for reimbursement, and this information is regis-
tered in a comprehensive database managed by the NHIS. 
The NHIS database also contains information on personal 
demographics and diagnoses identified by the International 
Classification of Diseases 10th revision (ICD-10) codes.
The Korean government provides additional financial sup-
port for patients diagnosed with a “Rare Incurable Disease,” 
including endometrial cancer, who are registered using a 
specific code for the “Exempted Calculation of Health Insur-
ance” based on a histopathologic evaluation. Accordingly, 
detecting patients with endometrial cancer using the cancer-
related ICD-10 codes combined with the additional code for 
the Rare Incurable Disease is considered to be reliable. 
Although RS is not covered by the NHIS in South Korea, it 
has been used in several gynecologic fields as an MIS since 
2006 [10]. Since data on the actual cost of RS are not avail-
able in the claims database, a direct cost comparison of the 
total cost according to the mode of surgery was not possible. 
Instead, a comparison was performed using costs claimed 
within 30 days of each surgery in the outpatient and emer-
gency department under the diagnosis of endometrial can-
cer.
2. Study population identification  
Women aged 18 years or older from the database were 
included in this analysis. Patients who had invalid data on 
hysterectomy, who had been diagnosed with other types of 
cancer at the time of hysterectomy, and who had missing 
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Fig. 1.  Flow diagram of the study population. IPTW, inverse probability of treatment weighting; mCCI, modified Charlson comorbidity 
index.
Patients diagnosed with primary endometrial cancer during
2012-2016 (n=21,583)
Endometrial cancer (n=5,081)
- Robotic (n=330, 6.5%)
- Laparoscopic (n=3,246, 63.9%)
- Open (n=1,505, 29.6%)
Endometrial cancer (n=5,065)
- Robotic (n=315, 6.2%)
- Laparoscopic (n=3,248, 64.1%)
- Open (n=1,503, 29.7%)
Exclusions
- Age ≤ 18 yr (n=2)
- Invalid data on hysterectomy (n=12,949)
    - No data (n=12,527)
    - Long time interval (over 90 percentile) between cancer
      diagnosis and hysterectomy (n=422) 
- Diagnosed with other types of cancer at the time of hysterectomy (n=1,365)
- Missing sociodemographic information (n=2,186)
IPTW adjusted for group, risk group (adjuvant therapy status), 
mCCI score, income level, insurance type, and index year
550     CANCER  RESEARCH  AND  TREATMENT
sociodemographic information were excluded.
Patients were assigned to each group with the following 
process. First, among the patients with endometrial cancer, 
women who had a general anesthesia code and a postop-
erative pathology examination code were selected. Then, 
patients who had both hysterectomy procedure and lapa-
roscopy material code were allotted to the LS group. The 
patients who had only hysterectomy procedure code without 
a laparoscopy material code were defined as the OS group. 
Finally, the RS group was defined as the absence of a hyster-
ectomy procedure code and a laparoscopy material code [11].
3. Confounding factors
Confounding factors were extracted from the database, 
including age group, risk group, modified Charlson comor-
bidity index (mCCI) score, income level, insurance type, 
and hysterectomy year. The risk group was determined 
according to whether the patients were treated with adjuvant 
therapy, including chemotherapy or radiotherapy, within 6 
months after discharge. Comorbidities were assessed using 
the mCCI, which differed from the standard Charlson comor- 
bidity index by excluding the subject’s age and presence or 
absence of kidney disease [12]. Comorbidities were consid-
ered to be confounding factors when there was a reported 
correlation between the concomitant chronic disease and the 
prognosis of cancer [13]. The diagnosis of a comorbidity was 
defined as a diagnosis at any visit within the one year prior 
to the hysterectomy date.
4. Statistical analysis  
To estimate unbiased causal treatment effects in the 
national cohort data, we used the inverse probability of 
treatment weighting (IPTW) method [14]. Demographic and 
tumor characteristics were compared using chi-squared 
tests. We used multivariable Cox proportional hazards mod-
els to determine the hazard ratio (HR) for predicting recur-
Kyung-Jin Eoh, Robotic, Laparoscopic, or Open Surgery in EM Cancer
Table 1.  Baseline characteristics for patients with endometrial cancer
Characteristic
 Total RS LS OS   p-value
 (n=5,065) (n=315) (n=3,248) (n=1,503) 
p-value
 RS vs. LS RS vs. OS LS vs. OS
Age (yr)
    ≤ 54  2,414 (47.7) 157 (50.0) 1,529 (47.1) 728 (48.4) 0.473 0.324 0.621 0.378
    ≥ 55  2,651 (52.3) 157 (50.0) 1,719 (52.9) 775 (51.6)    
Health insurance         
    Health insurance 4,941 (97.5) 309 (98.3) 3,166 (97.5) 1,466 (97.5) 0.647 0.351 0.386 0.939
    Medical aid 124 (2.5) 5 (1.7) 82 (2.5) 37 (2.5)    
Income level         
    High (> 25th percentile) 3,558 (70.2) 233 (74.1) 2,270 (69.9) 1,055 (70.2) 0.296 0.118 0.170 0.809
    Low (≤ 25th percentile) 1,507 (29.8) 82 (25.9) 978 (30.1) 447 (29.8)    
mCCI score         
    0-1 3,007 (59.4) 192 (61.0) 1,925 (59.3) 890 (59.2) 0.839 0.561 0.573 0.985
    ≥ 2 2,058 (40.6) 123 (39.0) 1,323 (40.7) 613 (40.8)    
Hysterectomy year         
    2012-2014 2,770 (54.7) 162 (51.4) 1,788 (55.0) 821 (54.6) 0.460 0.214 0.297 0.780
    2015-2016 2,295 (45.3) 153 (48.6) 1,460 (45.0) 682 (45.4)    
Risk group 
  (adjuvant therapy)         
    Low risk 4,062 (80.2) 255 (81.2) 2,603 (80.1) 1,204 (80.1) 0.905 0.659 0.672 0.997
    High risk 1,003 (19.8) 59 (18.8) 645 (19.9) 299 (19.9)    
Geographical location        
    Metropolitan 3,345 (66.0) 227 (72.2) 2,292 (70.6) 825 (54.9) < 0.001 0.539 < 0.001 < 0.001
    Other 1,721 (34.0) 87 (27.8) 956 (29.4) 678 (45.1)    
Chemotherapy 759 (15.0) 48 (15.2) 486 (15.0) 224 (14.9) 0.991 0.904 0.893 0.969
Radiotherapy 444 (8.8) 27 (8.5) 285 (8.8) 132 (8.8) 0.989 0.883 0.888 0.999
Chemotherapy and 199 (3.9) 16 (4.9) 126 (3.9) 58 (3.8) 0.642 0.364 0.369 0.939
  radiotherapy
Values are presented as number (%). LS, laparoscopic surgery; mCCI, modified Charlson Comorbidity Index; OS, open surgery; RS, robotic 
surgery.
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rence or death after adjustments for confounding variables. 
Progression-free survival (PFS) was defined as the duration, 
in days, from the date of surgery to the recurrence or end of 
follow-up, and overall survival was defined as the interval 
between the date of surgery and death or end of follow-up, 
whichever came first. The survival analysis was presented as 
Kaplan-Meier plots. p-values less than 0.017 (0.05/3=0.017) 
were considered significant for multiple testing (RS vs. LS, 
RS vs. OS, LS vs. OS). All statistical analyses were conducted 




After the IPTW adjustment, 5,065 patients with endome-
trial cancer treated with either RS (n=315, 6.2%), LS (n=3,248, 
64.1%), or OS (n=1,503, 29.7%) were included in the final 
analysis (Fig. 1). The three cohorts showed no significant dif-
ference in age group, risk group, type of health insurance, 
income level, mCCI score, comorbidities, and index year 
(Table 1). RS and LS were more likely than OS to be per-
formed in metropolitan hospitals (p < 0.001).
2. Recovery outcomes and postoperative morbidity
Postoperative complications occurred in 21patients (6.8%) 
in the RS group, 240 (7.4%) in the LS group, and 222 (14.8%) 
in the OS group, with the overall complication rate being sig-
nificantly lower in the MIS group (RS and LS) than in the 
OS group. Disorders of the lymphatic vessels, disruption of 
operation wounds, and intestinal obstruction were more com- 
mon in the OS group than in the other two groups (Table 2).
Patients in the MIS (RS and LS) groups showed earlier 
recovery with respect to the length of hospital stay than those 
in the OS group (RS vs. LS vs. OS: 10.2 days vs. 10.3 days 
vs. 13.8, respectively, p < 0.001). There was no difference 
between the RS and LS groups (Table 2).
3. Cost of outpatient and emergency room visits after sur-
gery
The number of outpatient visits was significantly lower in 
Cancer Res Treat. 2021;53(2):549-557
Table 2.  Hospital stay and postoperativecomplications
Characteristic
 Total RS LS OS   p-value
 (n=5,065) (n=315) (n=3,248) (n=1,503) 
p-value
 RS vs. LS RS vs. OS LS vs. OS
Length of stay (mean±SD) 11.3±7.4 10.2±6.1 10.3±7.1 13.8±7.8 < 0.001 1.000 < 0.001 < 0.001
Post-operative complications 483 (9.5) 21 (6.8) 240 (7.4) 222 (14.8) < 0.001 0.690 < 0.001 < 0.001
    Injury to bladder 4 (0.1) 0 ( 2 (0.1) 2 (0.1) 0.651 0.678 0.538 0.445
    Injury to ureter 4 (0.1) 0 ( 4 (0.1) 1 (0.0) 0.597 0.543 0.728 0.404
    Injury to colon and rectum 0 ( 0 ( 0 ( 0 (    
    Injury to blood vessels  3 (0.1) 0 ( 1 (0.0) 2 (0.1) 0.276 0.768 0.497 0.136
    Acute kidney failure 22 (0.4) 2 (0.5) 13 (0.4) 8 (0.5) 0.851 0.766 0.995 0.594
   Bladder disorder 19 (0.4) 2 (0.5) 9 (0.3) 9 (0.6) 0.246 0.414 0.919 0.103
    Vesicovaginal fistula 7 (0.1) 1 (0.3) 4 (0.1) 2 (0.1) 0.776 0.481 0.648 0.766
    Rectovaginal fistula 1 (0.0) 0 ( 1 (0.0) 0 ( 0.771 0.764  0.512
    Atelectasis 2 (0.0) 0 ( 1 (0.0) 1 (0.0) 0.935 0.760 0.725 0.863
    Vaginal vault prolapse 2 (0.0) 0 ( 1 (0.0) 1 (0.0) 0.935 0.760 0.725 0.863
    Disorders of lymphatic 263 (5.2) 15 (4.7) 124 (3.8) 125 (8.3) < 0.001 0.430 0.030 < 0.001
      vessels and lymph nodes
    Disruption of 75 (1.5) 2 (0.6) 37 (1.1) 36 (2.4) 0.001 0.366 0.039 0.001
      operation wound
    Sepsis 3 (0.1) 0 ( 1 (0.0) 2 (0.1) 0.381 0.761 0.526 0.201
    Pneumonia 26 (0.5) 1 (0.2) 15 (0.5) 10 (0.7) 0.428 0.447 0.282 0.347
    Embolism 36 (0.7) 0 ( 19 (0.6) 16 (1.1) 0.045 0.173 0.062 0.058
    Intestinal obstruction 35 (0.7) 0 ( 14 (0.4) 21 (1.4) < 0.001 0.239 0.035 0.000
    Hematoma 10 (0.2) 0 ( 4 (0.1) 6 (0.4) 0.156 0.517 0.277 0.091
    Post-traumatic 12 (0.2) 0 ( 7 (0.2) 5 (0.3) 0.504 0.415 0.311 0.457
      wound infection
Values are presented as number (%) unless otherwise indicated. LS, laparoscopic surgery; OS, open surgery; RS, robotic surgery; SD, 
standard deviation.
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the MIS group (RS and LS) compared with the OS group (2.9 
vs. 2.9 vs. 3.8 visits: RS vs. LS vs. OS, respectively, p < 0.001). 
In addition, the total cost of the visits was the lowest in the 
RS group ($298.00 vs. $348.66 vs. $532.69: RS vs. LS vs. OS, 
respectively, p < 0.001). The total cost of the emergency room 
visits after surgery was the lowest in the RS group ($633.14 
vs. $781.32 vs. $1,974.44: RS vs. LS vs. OS, respectively, 
p < 0.001). However, a significant difference was not noted 
between the RS and LS groups (Table 3).
4. Oncologic outcomes 
PFS was more favorable in the MIS (RS and LS) group than 
in the OS group (93.1%, 92.3%, and 87.5%, p < 0.001) (Fig. 
2A). The five-year overall survival was significantly long-
er for the RS and the LS group than the OS group (94.8%, 
91.9%, and 86.9%, respectively, p < 0.001) (Fig. 2B). Moreover, 
according to the univariate and multivariate analyses using 
the Cox proportional hazards model, the index surgery was 
a significant factor in predicting overall death, along with 
prognostic factors such as age group, mCCI score, and risk 
group (Table 4). The survival benefit of the RS was observed 
in the subgroup analysis for the low endometrial cancer risk 
group but not the high-risk group (S1 Table).
Discussion
This study compared the operative and oncologic out-
comes among open, laparoscopic, and robot-assisted staging 
surgeries in the era of a shift in the standard of care in endo-
metrial cancer management from the OS to MIS [5]. We found 
that robotic staging surgery did not seem to compromise sur-
gical or survival outcomes when compared to conventional 
laparoscopic and laparotomy for endometrial cancer. To the 
best of our knowledge, this population-based cohort study 
is the largest to compare the oncologic outcomes according 
to the three modes of surgery in endometrial cancer after the 
introduction of the RS to the field of gynecologic oncology.
Regarding recovery outcomes, postoperative complica-
tions, and cost after the index surgery, the RS was shown 
to be equivalent to the conventional LS and superior to the 
OS, which is in accordance with previous studies [15,16]. 
The reason for this finding may be the RS is gentler, causes 
minor damage to the internal organs, produces less postoper-
ative pain, and aids faster return to a normal diet and normal 
activities [17,18].
Any substantial change in the surgical approach to can-
cer management necessitates evaluation to ensure survival 
is not compromised. In terms of the survival outcomes of 
the MIS for endometrial cancer, most of the available stud-
ies compared the OS with the LS rather than with the RS 
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and indicated that laparoscopy was a favorable alternative 
for patients with endometrial cancer [3,19]. In the present 
study, we compared the survival outcomes between IPTW 
propensity score-matched groups of patients undergoing RS, 
LS, and OS after the introduction of robot-assisted LS. Our 
results showed that the adoption of the RS did not compro-
mise the survival outcomes compared with other modes of 
surgery.
Several studies have reported comparative long-term 
oncological outcomes between the OS and the RS for endo-
metrial cancer. Corrado et al. [20] observed that the 3-year 
overall survival was 86.7% and 91.5% and the 3-year PFS 
was 92.1% and 91.5% for OS and RS, respectively. Likewise, 
Cardenas-Goicoechea et al. [21] showed that there were no 
significant differences in survival between robotic and lapa-
roscopic surgeries (3-year PFS was 88.4% and 83.3% and 
3-year overall survival was 93.6% and 93.3% with LS and RS, 
respectively). Moreover, Brudie et al. [22] reported a 3-year 
PFS of 89.3% and 3-year overall survival of 89.1%, and Kil-
gore et al. [23] noted a 5-year overall survival of 89.1% in 
patients who underwent RS for endometrial cancer. In the 
present analysis, we demonstrated comparable survival out-
comes (5-year PFS, 93.1%, and 5-year overall survival, 94.8%) 
in the RS group.
Two randomized controlled trials (RCTs) and a large-scale 
meta-analysis have reported similar overall survival for the 
MIS and the OS, and that MIS is correlated with reduced 
surgical complications in non-metastatic endometrial can-
cer [3,19,24]. Though RCTs are accepted as having excellent 
internal validity, they do not necessarily describe the influ-
ence of a specific treatment in an entire population since frail 
subgroups tend to be excluded owing to strict inclusion crite-
ria for enrollment [25]. Our population-based study included 
the entire population of Korea who were treated under the 
diagnosis of endometrial cancer and a subgroup analysis 
was performed. Notably, our subgroup analysis indicated 
that the positive correlation between RS and favorable sur-
vival outcomes was present among low-risk patients, and 
similar survival was observed among high-risk women. This 
finding showed that the RS for endometrial cancer is, there-
fore, not only considered oncologically safe but is also likely 
to provide clear benefits for low-risk endometrial cancer 
patients in general.
Our results on the survival outcomes are consistent with 
those of the previously reported nationwide retrospective 
cohort study, which analyzed a population-based registry. 
Patients with early-stage endometrial cancer derived from 
the National Cancer Database of the United States were 
analyzed [26]. The overall survival after RS improved sig-
nificantly compared with OS when adjustments were made 
for age, surgical year, comorbidity, race, lymph-node yield, 
stage, adjuvant treatment, and economic status [26]. How-
ever, this analysis did not include patients treated with LS 
in the comparison. Another analysis of elderly middle-class 
patients with early-stage endometrial cancer from the reg-
istry of Medicare, a U.S. national insurance program, was 
performed, and comparable overall survival rates were 
observed for the MIS and the OS [27]. Unlike our study, this 
study did not distinguish between the RS and the LS, and the 
overall MIS was compared with the OS. The present study, 
encompassing 5,065 Korean patients with endometrial can-
cer, included all ages and socioeconomic statuses and found 
Cancer Res Treat. 2021;53(2):549-557
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Fig. 2.  IPTW-adjusted progression-free survival (A) and overall survival (B) for patients with endometrial cancer. IPTW, inverse prob-
ability of treatment weighting.
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that the RS and the LS were associated with improved sur-
vival compared with the OS.
We believe that our data are reliable for comparing the 
operative and oncologic outcomes in the real world because 
the cancer diagnostic codes and demographic variables reg-
istered in the Korean NHIS database are deemed accurate. 
Nevertheless, we should interpret the findings of our study 
in the context of the limitations associated with this nation-
wide retrospective study. For example, variables such as 
surgical stage or cell types, which may influence the onco-
logic outcomes of endometrial cancer, were not considered. 
The retrospective nature of our study and unmeasured con-
founding variables are major limitations. Also, the number 
of patients who underwent the RS was relatively small com-
pared to the LS or the OS. Further, potential selection bias, 
especially owing to the selection of patients who can under-
go RS, may also exist.
In conclusion, our nationwide cohort study provides fur-
ther evidence for the RS being a safe surgical alternative to 
the LS and the OS, especially in low-risk endometrial cancer 
patients, offering surgical and oncologic outcomes equiva-
lent to other surgical approaches.
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